6.9
Impella
®
System for Use During Cardiogenic Shock
Figure 6.6 Kaplan-Meier curve estimates for 30 day survival – All patient cohort
Figure 6.7 Kaplan-Meier curve estimates, 30 day survival (by device) - All patient
cohort
As a further breakdown of the survival outcomes, 29% of the patients expired on Impella device
support and 71% were successfully supported to recovery or to next therapy (bridge-to-bridge).
In aggregate, 45.7% were discharged (85.8% with recovery, 12.8% transferred to another
hospital on Impella support for care management and potential heart transplant or bridge-to-
transplant or destination therapy, 1.35% discharged on long-term implantable VAD). By device,
45%, 46% and 50% of the Impella patients survived to discharge for the Impella 2.5, CP and
5.0/LD, respectively. There was no observed difference in outcomes between the different
devices, but a trend for better outcomes was seen for patients treated with Impella 5.0/LD (see
Figure 6.7).
6
C
LIN
IC
A
L E
X
P
E
RI
E
N
C
E
Summary of Contents for Impella 2.5
Page 4: ......
Page 8: ......
Page 10: ......
Page 12: ......
Page 15: ...2 WARNINGS AND CAUTIONS WARNINGS 2 1 CAUTIONS 2 3...
Page 16: ......
Page 22: ......
Page 38: ......
Page 40: ......
Page 108: ......
Page 171: ......
Page 173: ......
Page 181: ......
Page 183: ......
Page 201: ......
Page 203: ......
Page 205: ......
Page 210: ...INDEX TBD...